ARK Investment Management LLC Has $139.41 Million Position in Illumina, Inc. $ILMN

ARK Investment Management LLC grew its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 25.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,467,879 shares of the life sciences company’s stock after purchasing an additional 299,801 shares during the quarter. ARK Investment Management LLC owned approximately 0.96% of Illumina worth $139,405,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. AQR Capital Management LLC raised its stake in shares of Illumina by 55.3% during the second quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock valued at $313,290,000 after acquiring an additional 1,174,295 shares during the last quarter. Edmond DE Rothschild Holding S.A. lifted its holdings in Illumina by 140.1% during the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 1,428,692 shares of the life sciences company’s stock worth $136,312,000 after buying an additional 833,750 shares during the period. Thrivent Financial for Lutherans grew its position in shares of Illumina by 1,558.0% in the 2nd quarter. Thrivent Financial for Lutherans now owns 728,755 shares of the life sciences company’s stock valued at $69,528,000 after buying an additional 684,802 shares during the last quarter. Pacer Advisors Inc. bought a new position in shares of Illumina during the third quarter worth about $61,663,000. Finally, Invesco Ltd. boosted its holdings in Illumina by 48.9% in the second quarter. Invesco Ltd. now owns 1,353,077 shares of the life sciences company’s stock valued at $129,097,000 after acquiring an additional 444,543 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Transactions at Illumina

In other Illumina news, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the transaction, the insider owned 17,887 shares in the company, valued at approximately $2,434,241.83. The trade was a 1.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the sale, the senior vice president directly owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms have issued reports on ILMN. Canaccord Genuity Group raised their price target on shares of Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a report on Monday, January 26th. Zacks Research downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. Barclays boosted their target price on shares of Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a report on Monday, December 15th. JPMorgan Chase & Co. decreased their price target on Illumina from $130.00 to $120.00 and set a “neutral” rating for the company in a report on Friday, February 6th. Finally, Guggenheim boosted their price objective on Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Six investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $129.69.

Illumina Price Performance

Shares of ILMN opened at $128.97 on Thursday. The business’s fifty day moving average is $134.74 and its 200 day moving average is $118.89. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $155.53. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55. The stock has a market cap of $19.72 billion, a P/E ratio of 23.66, a P/E/G ratio of 2.48 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.09. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The business’s revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.